BPC-157: Big Claims, Almost No Human Evidence

BPC-157 is one of the most hyped “healing peptides” in the recovery and longevity world. But once you set the marketing aside, there is surprisingly little human evidence to back it up.

What it is

BPC-157 (sometimes written “stable gastric pentadecapeptide BPC 157”) is a man-made chain of 15 amino acids (the small building blocks that make up proteins). Its sequence matches a piece of a protein found in human gastric juice (the fluid in your stomach), but the compound itself is made in a lab and is not known to occur naturally in this exact form. You will mostly find it sold as an injectable or oral “research chemical” through gray-market sellers (vendors operating in a legal gray area). It is not a dietary supplement, and it is not an approved drug.

The claims

Marketers pitch BPC-157 as a do-everything repair agent: faster healing of tendons, ligaments, muscle, and bone; gut healing (including for inflammatory bowel disease); less inflammation; and even brain-protecting and mood benefits. The idea behind how it supposedly works centers on encouraging angiogenesis (the growth of new blood vessels) and adjusting nitric oxide signaling (a chemical pathway the body uses to manage blood flow).

What the evidence actually shows

Nearly all the supporting research has been done in rats and other animals, or in cells grown in a dish. That body of work is actually quite large and often positive, reporting faster tissue healing and few obvious short-term harms in rodents. But there’s an important catch: a big chunk of it comes from one single research group (the lab of Predrag Sikirić in Croatia), and very few independent labs have repeated the results.

Human evidence is a different story. There are no published, peer-reviewed randomized controlled trials (carefully designed studies that compare the treatment against a placebo). The few human reports that do exist are tiny (roughly 2 to 16 people each, well under 30 people total across every published study), have no comparison groups, and come from a single group of clinicians. A Phase 1 trial (an early, first-in-people safety study) of BPC-157 was registered in 2015 but cancelled in 2016 with no published results. Older Croatian (PLIVA) work on a related formulation (PL 14736) for ulcerative colitis — including a randomized, placebo-controlled enema study — was presented at conferences but does not seem to appear as a peer-reviewed publication in major databases, so no one outside that group can check the results. In short, the impressive animal data has not been confirmed in well-designed human studies. Even the basics of human pharmacokinetics (how the body absorbs, doses, and clears the compound) are still largely unknown.

A handful of tiny, uncontrolled pilot reports just isn’t enough to count as real “preliminary human” evidence. With no comparison groups, no independent repetition, and only one source, they can’t tell us whether BPC-157 actually works in people. So the honest grade rests on the animal research.

Legal and regulatory status

A few separate facts often get tangled together here, so let’s take them one at a time.

BPC-157 is not approved by the FDA for any use. In 2023 the FDA placed it on its Category 2 list of “bulk drug substances that may present significant safety risks.” In plain terms, that told compounding pharmacies (which custom-mix medications) not to make it, citing concerns about immunogenicity (the risk of triggering an unwanted immune reaction), peptide-related impurities, and limited human safety data.

Things shifted in 2026. In April 2026 the FDA took BPC-157 off that Category 2 list, along with 11 other peptides (12 in total), and scheduled a Pharmacy Compounding Advisory Committee review for July 23–24, 2026. Here’s the key point: being removed from Category 2 does not mean it was approved, and it does not by itself make it legal to compound. As of June 2026 it sits in a gray zone — no longer formally flagged as a safety-risk substance, but not added to the 503A bulks list that would actually allow compounding, and still not an approved drug.

It also remains banned in sport. The U.S. Anti-Doping Agency and WADA prohibit BPC-157 at all times under category S0 (non-approved substances), with no way to get a therapeutic use exemption (special permission to use an otherwise-banned substance). Athletes have been penalized for using it, including a publicly reported UFC case.

Safety

The honest answer is that we don’t know its long-term safety in humans. There are no large or long-term human safety studies. One concern that keeps coming up, at least in theory: a compound that encourages blood-vessel growth could, in principle, also help feed tumors — though there’s no human evidence either confirming or ruling this out. The FDA has flagged immune reactions and impurities, and because the supply is gray-market, products may be mislabeled or contaminated. Some users report itching, anxiety, and low mood, but these accounts are uncontrolled and don’t prove the peptide caused them.

Bottom line

BPC-157 has a large, encouraging body of animal research and a devoted following, but the human evidence we’d need to call it safe or effective simply isn’t there yet. It is unapproved, its regulatory status keeps changing, and it is banned for competitive athletes. Treat the excitement as a hypothesis, not a proven result. This is not medical advice.

Evidence grade: 4/10 · Animal-leaning.

Sources

• BPC-157: Experimental Peptide Creates Risk for Athletes (USADA)
• BPC-157: The peptide with big claims and scant evidence (STAT News, Feb 2026)
• Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (FDA)
• Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (FDA)
• FDA to Remove 12 Peptides from the Category 2 “Do Not Compound” List (Frier Levitt, 2026)
• The Prohibited List (World Anti-Doping Agency)
• BPC-157: A prohibited peptide and an unapproved drug found in health and wellness products (OPSS, DoD)